|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane显示文摘 | Buzdar AU Robertson JF Eiermann W | 2002 | Cancer2002，95，9： | 1 |
| 2 | The use of gonadotrophin-releasing hormone(GnRH) agonists in early and advanced breast cancer in pre- and perimenopansal women 显示文摘 | Robertson JF Blamey RW | 2003 | Eur J Cancer2003，39，7： | 1 |
| 3 | c-erbB-2 expression in primary breast cancer显示文摘 | Menard S Robertson JF | 1999 | Int J Biol Markers1999，14，1： | 1 |
| 4 | Goserelin (Zoladex)in premenopausal advanced breast cancer: duration of response and survival显示文摘 | Robertson JF Jackson L | 1990 | Br J Cancer1990，62，5： | 1 |
| 5 | Endocrine treatment options for advanced breast cancer--the role of fulvestrant 显示文摘 | Robertson JF Come SE Jones SE | 2005 | Eur J Cancer2005，41，3： | 1 |
| 6 | Fulvestrant,foremerly ICI182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment 显示文摘 | Howell A Robertson JF Quaresma Albano J | 2002 | J Clin Oneol2002，20，16： | 1 |
| 7 | The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer 显示文摘 | Robertson JF Willsher PC Cheung KL | 1997 | Eur J Cancer1997，33，11： | 1 |
| 8 | Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer显示文摘 | Robertson JF Watson SA Hardcastle JD | 1995 | Int J Cancer1995，63，1： | 1 |
| 9 | Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer:results from the FIRST study显示文摘 | Robertson JF Llombart-Cussac A Rolski J | 2009 | J Clin Oncol2009，27，27： | 1 |
| 10 | The clinical relevanc of static disease ( no change) category for 6 months on endocrine therapy in patients with breast cancer显示文摘 | Robertson JF Willsher PC Cheung KL | 1997 | Eur JCancer1997，33，11： | 1 |
| 11 | Pleural effusion in breast cancer: a review of the Nottingham experience显示文摘 | Banerjee AK Willets I Robertson JF | 1994 | Eur J Surg Oncol1994，20，1： | 1 |
| 12 | An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane显示文摘 | Buzdar AU Robertson JF Eiermann W etal | 2002 | Cancer2002，，： | 1 |
| 13 | Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials 显示文摘 | Robertson JF Osborne CK Howell A | 2003 | Cancer2003，98，2： | 1 |
| 14 | Fulvestrant is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment显示文摘 | Howell A Robertson JF Quaresma A | 2002 | J Clin Oncol2002，20，16： | 1 |
| 15 | Preoperative endocrine therapy for breast cancer显示文摘 | Howell A Robertson JF | 2007 | Endocr Cancer2007，7，： | 1 |
| 16 | Early-onset breast cancer:histopathological and prognostic consideration显示文摘 | Kollias JEC Ellis IO Robertson JF | 1997 | Br J Cancer1997，75，： | 1 |
| 17 | Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial显示文摘 | Howell A Robertson JF Abram P | 2004 | J Clin Oncol2004，22，9： | 1 |
| 18 | Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer 显示文摘 | Robertson JF Erikstein B Osborne KC | 2004 | Clin Pharmacokinet2004，43，8： | 1 |
| 19 | Comparison of the short-term biological effects of 7 alpha- estra-1 ,3,5, (10) -triene-3 , 17 beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer 显示文摘 | Robertson JF Nicholson RI Bundred NJ | 2001 | Cancer Res2001，61，18： | 1 |
| 20 | Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates显示文摘 | Borisoff JF Chan CC Hiebert GW Oschipok L Robertson GS Zamboni R | 2003 | Mol Cell Neurosei2003，22，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员